| INTRODUC TI ON
The detection of "de novo" donor-specific anti-HLA antibodies (DSAs) has been associated with worse outcomes in adult heart, kidney, and lung transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The pediatric experience is limited to small, single-center, predominantly retrospective cohorts, frequently with irregular sampling times, and with varying follow-up and outcomes. [12] [13] [14] [15] [16] The term "de novo DSA" has been used interchangeably with "newly detected DSA" in the literature. Testing to identify an antibody as truly de novo is often not reported or not available due to the lack of assessment of pretransplantation antibody presence or specificity. Arbitrary thresholds for identifying a pretransplantation HLA antibody can also lead to a result that falls below threshold and thus is deemed "not present." When such an antibody "reappears" in later testing, it can be misclassified as de novo when it is truly reflective of a memory response. To avoid inferences about primary versus memory immune responses, we have chosen to use the term newly detected DSA (ndDSA) throughout this study.
No large, prospective multi-institutional studies have established the incidence of ndDSAs after pediatric heart transplantation or studied their impact on outcomes. The cardiac consortium of the National
Institute of Allergy and Infectious Diseases/National Institutes of Health-sponsored Clinical Trials in Organ Transplantation in Children (CTOTC) program (www.ctotc.org) was developed to explore the impact of alloantibodies on pretransplantation and posttransplantation outcomes in pediatric heart candidates, with a focus on the management of the highly sensitized candidate including those with a positive donor-specific cytotoxicity crossmatch (CDC-XM). 17, 18 Study design, candidate sensitization status, risk factors for sensitization, and primary outcomes from CTOTC-04 are described elsewhere in this volume. 17, 18 CTOTC-04 also provides a unique opportunity to study the clinical importance of ndDSAs in the first year after pediatric heart transplantation.
We hypothesized that the presence of ndDSAs in the first year after pediatric heart transplantation would be common in both nonsensitized and sensitized subjects and would be associated with increased rates of both acute cellular rejection (ACR) and antibodymediated rejection (AMR) but would not affect short-term graft and patient survival rates. The specific aims of this analysis were to (1) determine the incidence, characteristics, and time course of ndDSAs in the first year after pediatric heart transplantation, 
| MATERIAL AND ME THODS

| Overview of study design and participants
The CTOTC-04 multicenter pediatric heart transplant study prospectively recruited consecutive patients (age <21 years) listed for heart transplantation at 8 large pediatric centers. All study activities were approved by the institutional review boards at each participating center. heart transplantation and patients with a history of a sensitizing event may be at risk even with a negative pretransplantation antibody screen. The impact on late graft and patient outcomes of first-year ndDSAs is being assessed in an extended cohort of patients.
K E Y W O R D S
clinical research/practice, heart transplantation/cardiology, monitoring: immune, patient survival, pediatrics, rejection: acute, rejection: antibody-mediated (ABMR), sensitization we retrospectively performed single-antigen bead testing on the "negative" samples at the time of transplantation so that all patients ultimately had results based on single-antigen bead testing ( Figure 1 ).
Donor and recipient molecular typing was performed by using low-resolution molecular technique, including for HLA-C and -DQ.
There was variable availability of -DP molecular typing and HLA-DP antibodies were assessed for DSA status only when donor and recipient -DP typing was available. For this substudy, all HLA antibody determinations were performed in batched fashion at the Alloantibody Core Laboratory by a single senior technician, and all DSA determinations were made by a single senior investigator (AZ, UPMC).
Posttransplantation ndDSAs were defined as occurring "early"
(≥6 days to <42 days) or "late" (≥ 42 days). These categories were not mutually exclusive where there were multiple ndDSAs. The few patients who had both early and late ndDSAs (n = 7) were counted only in the early ndDSA group for the purpose of the outcomes analyses 
| Statistical analysis
To mitigate the potential clinical impact of pretransplantation HLA antibodies, several groups were identified for analysis ( Figure 1 and then for any late ndDSAs. Risk factors were identified using a backward elimination variable selection strategy with α = 0.10 threshold for inclusion in the model. Variables included in the model were age at transplantation, weight at transplantation, diagnosis, race, sex, UNOS status at transplantation, prior surgery, prior blood transfusion, ventricular assist device (VAD), extracorporeal membrane oxygenation, homograft, prior transplantation, and sensitization status at transplantation. All statistical analyses were performed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC).
| RE SULTS
| Participant population
From February 2011 to December 2013, 240 patients underwent heart transplantation of which 237 (53% males and 44% with congenital heart disease [CHD]) had pretransplantation samples for HLA antibody detection.
17 Median age at heart transplantation was 6 years (1 month to 20 years). Demographic information for the groups considered in this analysis is detailed in Table 1 .
There were 1599 total posttransplantation serum samples collected between 6 and 365 days posttransplantation and screened for ndDSAs. Nine hundred sixty-six (60%) samples were collected at scheduled visits, and 633 (40%) were collected at other times. Median follow-up time posttransplantation was 741 days
(1-1275 days), although analysis for this study ends at the 1-year posttransplantation visit.
| Impact of timing of samples
To explore any potential bias introduced by varying sampling times (40% at unscheduled visits) on the distribution of early, late, and no ndDSAs, the analysis was repeated to include only samples obtained at scheduled visits. There was minimal impact, with 2 patients recategorized from the late group to the no ndDSA group. Thus, the results presented are based on all 1599 samples.
| Frequency, time course, and characteristics of ndDSAs
The ndDSAs were detected in 80 (34%) participants within the first year after heart transplantation: 61 (26%) early and 19 (8%) late (Table 1 , Figure 1 ). Among the pretransplantation DSA-negative cohort (n = 186, Figure 1 ), 55 (30%) patients developed ndDSAs (39 early, 16 late). There were no significant differences in sex between the ndDSA groups though participants with a diagnosis of CHD and of older age were more likely to have early ndDSAs (P = .01 and P = .04, respectively). Pretransplantation sensitization was significantly associated with the detection of ndDSAs (P = .03). There was no significant difference in maximal MFI between the early and late groups. Patients with both early and late ndDSAs are included in the ndDSA category. The median (minimum -maximum) is presented for continuous variables.
No P-value was calculated for time to detection of ndDSAs because the groups were defined based on this criterion and hence will be statistically different. CHD, congenital heart disease; MFI, median fluorescence intensity. a Early (6 to <42 days); late (≥42 days).
posttransplantation. Among the early group, approximately threequarters of responses were observed within the first 2 weeks. We hypothesized that early ndDSAs are memory responses and that in some cases, at least, we would be able to demonstrate retrospectively the presence of the same DSAs on pretransplantation samples that had initially been deemed negative by using the Luminex Table S1 . MFI (range) for transient DSAs was 1800 (1000-19 100) compared with 3400 (1000-21 000) at first detection of persistent antibodies (P = .0012). Maximal MFI (range)
for persistent antibodies was 4800 (1000-22 400). 18 we proceeded to analyze rejection outcomes in the cohort of 186 subjects without pretransplantation DSAs (see Figure 1) . Figure 3 
| Rejection
| Graft and patient survival
Overall, 21 patients (9%) died (15 in the first year, 4 in the second year, and 2 beyond the second year posttransplantation). The presence of ndDSAs was not associated with statistically significant differences in first year patient survival regardless of the status by pretransplantation DSAs ( Figure 5 ). Two patients underwent retransplantation (one each in the first year and second year posttransplantation), both of whom were not sensitized pretransplantation but developed early ndDSAs; the numbers are too small to make any comments beyond reporting this observation.
| Primary study endpoint stratified by ndDSA status
There was no difference between the groups for the primary study composite endpoint of death, retransplantation, or rejection with hemodynamic compromise at 1 year posttransplantation. This analysis was repeated focusing on the subjects with persistent ndDSAs with similar findings (Supplemental Figures 2 and 3 ).
| Risk factors for the development of ndDSAs
Risk factors for the development of any ndDSAs included prior homograft, absence of VAD prior to transplant, and increased age at Number of subjects with acute rejection "events" (%) ndDSA, newly detected donor-specific anti-HLA antibody.
a Some patients had multiple rejection events of different types and therefore are represented more than once.
transplant (Table 4) . Risk factors for the development of early ndDSAs were similar, with the addition of prior transplantation and CHD diagnosis. Risk factors for the development of late ndDSAs could not be determined due to the small number of events.
| D ISCUSS I ON
We leveraged the detailed pretransplantation and posttransplantation data and frequent sample collection from the CTOTC-04 study to provide the first detailed analysis of the incidence, time course, antibody characteristics, and clinical impact of ndDSAs in a large cohort of pediatric heart transplant candidates and recipients. We have also been able to adjust for the confounding impact of the presence of pretransplantation DSAs because > 180 patients without pretransplantation antibodies are being followed. Our findings include several new observations. Of note, throughout, we have used the term "newly detected" DSAs (ndDSAs) rather than "de novo" DSAs to avoid any a priori assumptions about the nature of these antibodies.
In our cohort, one-third had evidence of ndDSAs within the first year post heart transplantation. Reports in the literature cite that "de novo" DSAs are common after heart transplantation and associated with poor outcomes. 1,10,14 Several studies report de novo HLA antibodies in 25-33% of adult heart transplant recipients. 
tion.
12-16 A number of cohorts had longer follow up than our cohort but still the majority of de novo DSAs were detected in the first year posttransplantation. 1, 10, 14, 16 We intend to follow our cohort in the long term to establish the incidence of ndDSAs beyond 1 year and to assess the late impact of these antibodies.
Prior sensitization as a risk for the development of de novo DSAs
has been noted in other smaller series. 10, 15 The finding, herein, that VAD use was associated with a lower incidence of ndDSAs seems contradictory to the increasing evidence in the literature that VAD C use is associated with allosensitization. [22] [23] [24] [25] One could hypothesize VAD use is a surrogate for a diagnosis of cardiomyopathy, which has a lower risk of developing ndDSAs compared with CHD.
The majority of these ndDSAs were detected early (ie, within 6 weeks) of transplantation and thus are most consistent with memory response as opposed to a primary immune response. In a significant minority of those with early ndDSAs, we were able to retrospectively demonstrate that the same antibody had been present at a very low strength pretransplantation, confirming the memory response. We suspect that we would have been able to demonstrate this in more patients if there were more historical samples from nearer the time of sensitizing events, such as prior surgery for CHD.
Of note, in this population, early responses predominated with only 19 subjects demonstrating ndDSAs beyond 6 weeks and 11 after 3 months from transplantation. This suggests we should exercise caution in assuming that pediatric heart candidates with a negative The persistence of ndDSAs likely has an impact on outcome.
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Nearly all early ndDSAs in this cohort were no longer detected beyond 3 months posttransplantation. This contrasts with adult heart data in which most de novo DSAs (84%) were persistent and associated with poor survival compared with transient DSAs. 1 In the 3 pediatric patients reported by Irving and colleagues with persistent DSAs, all experienced graft loss. 10 However, prior reports were generally associated with longer follow-up than the current cohort. We observed persistent ndDSAs in 70% of our cohort. Overall clinical F I G U R E 4 Time course of posttransplantation newly detected donor-specific anti-HLA antibodies (DSAs) in relation to rejection events. Subjects without DSAs pretransplantation (n = 55). The timing of the first ndDSA is represented by a blue star, with timing and type of rejection depicted by colored circles outcomes were similar whether we examined all subjects together or only those with persistent ndDSAs, with the latter, however, having lower freedom from ACR.
Rejection has been implicated in the kidney literature as a stimulus for the development of de novo DSAs. 7, 10, 27, 28 In an adult cardiac population, rejection occurred predominantly in the first year posttransplantation, but de novo DSA production was noted on an ongoing basis every year posttransplantation.
Late de novo
DSAs were associated with the number of biopsy-proved rejection episodes in the first year, and the authors concluded that this was supportive for rejection as a stimulus for antibody production. The retrospective nature of many studies and the annual or irregular sampling for DSAs compromise the ability to discern the true temporal relationship between DSA development and rejection episodes.
1,10
Chen and associates observed the majority of antibody detection before or concurrent with an episode of ACR in a small cohort of pediatric heart transplant recipients. 16 We also observed that ndDSAs were usually detected either before or concurrent with episodes of rejection in our prospectively followed patient cohort. Although speculative, this leads to the consideration that the association of ndDSAs with rejection is more likely to be causative as opposed to a secondary epiphenomenon. This presumed causal relationship does not preclude the potential for tissue damage induced by DSAs leading to further release of soluble alloantigens (and autoantigens) with subsequent enhanced sensitization.
In the current study, ndDSAs were associated with increased risk of ACR but not AMR. In contrast, we previously showed in this same cohort that pretransplantation DSAs and CDC-XM status have an impact on both ACR and AMR. 18 The lack of association of ndDSAs with AMR was contrary to our initial hypothesis; most of the AMR episodes observed in this study were associated with preformed DSAs. 18 Of note, Clerkin and colleagues reported a cohort of 221 adult heart transplant recipients of whom 31% had DSAs (24% de novo DSAs) and found no correlation between presence of DSAs (preexisting or de novo) and concurrent pathologic changes of AMR on biopsy.
3 Although in our study ndDSAs were associated with increased ACR, these findings are insufficient at this time to provide recommendations on how to treat asymptomatic pediatric heart recipients who develop ndDSAs. Randomized clinical trials will be required to address this critical question, although it is unlikely that they can be adequately powered in a pediatric population.
Interestingly, there is a sizeable proportion of our cohort who did not develop AMR or ACR despite the development of ndDSAs. Thus, even though ndDSAs represent a risk factor for the development of ACR, more must be learned before we can accurately predict which patients and which antibody profiles are likely to lead to acute graft injury. Ongoing studies within CTOTC-04 are exploring which patient and antibody characteristics (eg, Ig subtype, class, complement fixing ability, concentration, strength) may better predict who is most at risk of adverse outcomes and, thus, who should be treated more aggressively. Of note, neither pretransplantation DSAs nor posttransplantation ndDSAs had an impact on 1-year graft and patient survival nrates or the primary composite endpoint (death, retransplantation, or rejection with hemodynamic compromise). Longerterm follow-up of an expanded cohort of patients within CTOTC will establish the long-term impact of ndDSAs in pediatric heart candidates. There is certainly evidence from research on many organs that de novo DSA development is associated with subsequent development of graft vasculopathy, graft dysfunction, and, ultimately, graft loss. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 29 Cardiac allograft vasculopathy after heart transplantation has been associated with de novo DSAs, particularly class II. 3, 12, 14, 30 Within CTOTC, a Coronary Angiography Core is currently being used during long-term follow-up of this cohort.
| Limitations
Although this is a large, prospective study of pediatric heart recipients, the patient population remains too small for robust subgroup analyses, particularly for late ndDSAs. This limitation is being addressed within the larger cohort in our long-term CTOTC-09 study.
The prevalence of ndDSAs may be underestimated, beause it was not always possible to determine if HLA-DP antibodies were donor specific, given the incomplete typing for -DP. Nonetheless, -DP antibodies appear rare in this population (of the 54 patients with donors with -DP typing, there were 2 with preformed DSAs and 1 who developed a -DP DSA posttransplantation [data not reported]), which is in keeping with a previously reported large cohort of pediatric renal transplant recipients.
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In addition, we are not able to prove or disprove passive antibody transfer as a source of ndDSAs early after transplantation. If early antibodies were the result of pretransplantation transfusion, we would have detected them during single-antigen bead testing at transplantation. If they were transferred perioperatively, we might expect to see evidence of "self-reactivity" in the early posttransplantation alloantibody profiles. We are also not aware of data that suggest that passive transfer of HLA antibody via blood products in this clinical setting causes early ACR, yet ndDSAs were associated with ACR in this study. We also acknowledge that any cutoff time point for "early" versus "late" ndDSAs is somewhat arbitrary, although we believe that a 6-week time point is well accepted in the field as reflective of the time frame to observe a memory response, whereas for newly developed antibody (true de novo), the minimal time is generally considered to be greater than 6 weeks. However, to avoid making inferences about the nature of the antibody response ("memory," "de novo," "passive") in any specific patient, we have chosen to consistently use the term "newly detected" (nd) when reporting our results. Of note, if a cutoff of 3 months were used to define the late group (as has been performed in some studies), there would have been only 11 subjects in the late group.
Finally, in this initial report, follow-up is limited to the first year posttransplantation; therefore, we are not in a position at this time to evaluate the impact of first-year ndDSAs on late outcomes.
More-detailed antibody characterization (eg, IgG subtype, complement fixing ability, and titer) was not part of this analysis yet may be of greater predictive value than MFI of DSAs for clinical outcomes. To overcome these limitations, we continue to study an expanded cohort of patients within our long-term CTOTC-09 study (which includes these CTOTC-04 subjects). This follow-up study includes echocardiographic assessment of graft function and angiographic assessment of graft coronary vasculopathy using core laboratories for independent evaluation of the impact of DSAs on graft outcomes.
| CON CLUS ION
In this large, multicenter prospective cohort, most pediatric heart transplant recipients did not develop ndDSAs within the first year after transplantation. When present, these were mostly detected within the first 6 weeks after transplantation, suggesting that memory responses may predominate over true de novo DSA production in this population. Patients with neither pretransplantation DSAs nor ndDSAs had the highest freedom from all forms of rejection. The ndDSAs were associated with increased risk of ACR but not AMR.
The impacts on late graft and patient outcomes of first-year ndDSAs are being assessed in an extended cohort of patients within the CTOTC consortium. 
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